Anwendungsgebiet
Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.
- Ordspono 2 MG Concentrado Para Solucion Para PerfusionSpanien · 2 mgZugelassen
- Ordspono 320 MG Concentrado Para Solucion Para PerfusionSpanien · 320 mgZugelassen
- Ordspono 80 MG Concentrado Para Solucion Para PerfusionSpanien · 80 mgZugelassen
- Ordspono 2 mg concentraat voor oplossing voor infusieNiederlandeZugelassen